Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.49 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.47 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | EDNRB | P24530 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | MC3R | P41968 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21516127 | 0.84 | GABBR2 (0.50) | CYP2D6CYP2C19GABBR2GABBR1LMNA | |
| SCHEMBL7537470 | 0.84 | GABBR2 (0.50) | CYP2D6CYP2C19GABBR2GABBR1LMNA | |
| SCHEMBL27556646 | 0.81 | ALDH1A1 (0.44) | CYP2D6CYP2C19GABBR2GABBR1ALDH1A1 | |
| SCHEMBL27146428 | 0.80 | CYP1A2 (0.64) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL9105247 | 0.79 | ALDH1A1 (0.63) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL436598 | 0.79 | TSHR (0.53) | CYP1A2SMN1; SMN2NPSR1CYP2C19ALDH1A1 | |
| SCHEMBL27601244 | 0.78 | HPGD (0.40) | CYP2D6CYP2C19GABBR2GABBR1ALDH1A1 | |
| SCHEMBL28747890 | 0.78 | CYP2D6 (0.51) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 | |
| SCHEMBL25627210 | 0.78 | CYP2D6 (0.41) | CYP2D6CYP2C19GABBR2GABBR1LMNA | |
| SCHEMBL1383474 | 0.77 | CYP2C19 (0.67) | CYP2D6CYP1A2PKMSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190391092-A1 | METABOLIC PROFILING WITH MAGNETIC RESONANCE MASS SPECTROMETRY (MRMS) | Oregon Institute of Science and Medicine | 2019-12-26 | — | — | US | disclosed |
| WO-2015100252-A1 | DEUTERATED FELBAMATE, COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USE THEREOF | PEROSPHERE, INC. (US) | 2015-07-02 | — | — | WO | disclosed |
| EP-1337218-A4 | SUBSTITUTED FELBAMATE DERIVED COMPOUNDS | UNIV VIRGINIA (US) | 2005-08-10 | — | — | EP | disclosed |
| EP-1282414-B1 | FELBAMATE DERIVED COMPOUNDS FOR TREATING NEUROPATHIC PAIN | UNIV VIRGINIA (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6759402-B2 | ELIMINATING TOXICITY EFFECT; EPILEPTIC SEIZURES; ANTIISCHEMIC AGENTS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2004-07-06 | — | — | US | disclosed |
| US-20040023986-A1 | Substituted felbamate derived compounds | GENERAL ELECTRIC CAPITAL CORPORATION | 2004-02-05 | — | — | US | disclosed |
| US-20030229086-A1 | Cyclic felbamate derived compounds | MACDONALD TIMOTHY L (US) | 2003-12-11 | — | — | US | disclosed |
| US-20030166648-A1 | Felbamate derived compounds | GENERAL ELECTRIC CAPITAL CORPORATION | 2003-09-04 | — | — | US | disclosed |
| EP-1337218-A2 | SUBSTITUTED FELBAMATE DERIVED COMPOUNDS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2003-08-27 | — | — | EP | disclosed |
| US-6599935-B2 | 2-phenyl-1,3-propanediol dicarbamate derivatives used as antiepileptic and antiischemic agents | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2003-07-29 | — | — | US | disclosed |
| EP-1156798-B1 | FELBAMATE DERIVED COMPOUNDS | UNIV VIRGINIA (US) | 2003-07-09 | — | — | EP | disclosed |
| US-6538024-B1 | The present invention relates to novel felbamate derivatives and their use to treat neurological diseases such as epilepsy and to treat tissue damage resulting form ischemic events. The felbamate derivatives are modified to prevent the | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2003-03-25 | — | — | US | disclosed |
| EP-1282414-A2 | FELBAMATE DERIVED COMPOUNDS | University of Virginia Patent Foundation (US) | 2003-02-12 | — | — | EP | disclosed |
| US-20020156070-A1 | Felbamate derived compounds | VIRGINIA, UNIVERSITY OF | 2002-10-24 | — | — | US | disclosed |
| WO-2002056827-A2 | SUBSTITUTED FELBAMATE DERIVED COMPOUNDS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2002-07-25 | — | — | WO | disclosed |
| EP-1156798-A4 | FELBAMATE DERIVED COMPOUNDS | UNIV VIRGINIA (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-1156798-A1 | FELBAMATE DERIVED COMPOUNDS | THE UNIVERSITY OF VIRGINIA ALUMNI PATENTS FOUNDATION (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2001085149-A2 | FELBAMATE DERIVED COMPOUNDS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2001-11-15 | — | — | WO | disclosed |
| WO-2000047202-A1 | FELBAMATE DERIVED COMPOUNDS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156070-A1 | Felbamate derived compounds | ABAT, NLN, GABRB1 | CYP2D6 624/4885CYP1A2 713/4885PKM 942/4885 |
| US-20030166648-A1 | Felbamate derived compounds | FAAH, FFAR4, FFAR3 | CYP2D6 1074/4885CYP1A2 2319/4885PKM 2272/4885 |
| US-20040023986-A1 | Substituted felbamate derived compounds | CACNA1B, GABRB1, GABRB3 | CYP2D6 395/4885CYP1A2 928/4885PKM 952/4885 |
| US-20030229086-A1 | Cyclic felbamate derived compounds | NLN, GABRB1, ABAT | CYP2D6 1095/4885CYP1A2 896/4885PKM 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.